Dominique Costagliola1, Jean-Marc Lacombe1, Jade Ghosn2, Constance Delaugerre3, Gilles Pialoux4, Lise Cuzin5, Odile Launay6, Amélie Ménard7, Pierre de Truchis8, Murielle Mary-Krause1, Laurence Weiss9, Jean-François Delfraissy10. 1. INSERM and Sorbonne Universités, UPMC Paris Univ 06, Pierre Louis Institute, UMR-S 1136, Paris, France. 2. AP-HP, Hotel-Dieu, Université Paris Descartes, Paris, France. 3. AP-HP, Hôpital Saint-Louis, Université Paris Diderot et INSERM, Paris, France. 4. AP-HP, Hôpital Tenon, Service de Maladies Infectieuses, Paris, France. 5. CHU Toulouse, Service de Maladies Infectieuses, Toulouse, France. 6. AP-HP, Hôpital Cochin, Fédération d'Infectiologie, Paris, France. 7. AP-HM, Hôpital de la Conception, Service de Maladies Infectieuses, Marseille, France. 8. AP-HP, Hôpital Raymond Poincaré, Service de Maladies Infectieuses, Garches, France. 9. AP-HP, Hôpital Européen Georges Pompidou, Institut Pasteur, Paris, France. 10. Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Paris, France.
Abstract
INTRODUCTION: A key objective of combined antiretroviral therapy (cART) is to reach and maintain high CD4 cell counts to provide long-term protection against AIDS-defining opportunistic infections and malignancies, as well as other comorbidities. However, a high proportion of patients present late for care. Our objective was to assess CD4 cell count recovery up to seven years in naïve patients initiating cART with at least three drugs in usual clinical care. METHODS: From the French Hospital Database on HIV, we selected naïve individuals initiating cART from 2000 with at least two years of follow-up. Participants were further required to have achieved viral load suppression by six months after initiating cART and were censored in case of virological failure. We calculated the proportion of patients (Kaplan-Meier estimates) who achieved CD4 recovery to >500/mm(3) according to baseline CD4 cell count. RESULTS: A total of 15,025 patients were analyzed with a median follow-up on ART of 65.5 months (IQR: 42.3-96.0). At cART initiation, the median age was 38.6 years (IQR: 32.2-46.0), 9734 (64.8%) were men, median CD4 cell count was 239 (IQR: 130-336) and 2668 (17.8%) had a prior AIDS event. RESULTS are presented in the Table 1. CONCLUSIONS: This study shows that CD4 cell counts continue to increase seven years after cART initiation, whatever the baseline CD4 cell count. Failing to achieve CD4 recovery with continuous viral load suppression is rare for naïve patients initiating cART in routine clinical practice, but takes substantially longer in patients who initiate antiretroviral therapy at low CD4 cell counts.
INTRODUCTION: A key objective of combined antiretroviral therapy (cART) is to reach and maintain high CD4 cell counts to provide long-term protection against AIDS-defining opportunistic infections and malignancies, as well as other comorbidities. However, a high proportion of patients present late for care. Our objective was to assess CD4 cell count recovery up to seven years in naïve patients initiating cART with at least three drugs in usual clinical care. METHODS: From the French Hospital Database on HIV, we selected naïve individuals initiating cART from 2000 with at least two years of follow-up. Participants were further required to have achieved viral load suppression by six months after initiating cART and were censored in case of virological failure. We calculated the proportion of patients (Kaplan-Meier estimates) who achieved CD4 recovery to >500/mm(3) according to baseline CD4 cell count. RESULTS: A total of 15,025 patients were analyzed with a median follow-up on ART of 65.5 months (IQR: 42.3-96.0). At cART initiation, the median age was 38.6 years (IQR: 32.2-46.0), 9734 (64.8%) were men, median CD4 cell count was 239 (IQR: 130-336) and 2668 (17.8%) had a prior AIDS event. RESULTS are presented in the Table 1. CONCLUSIONS: This study shows that CD4 cell counts continue to increase seven years after cART initiation, whatever the baseline CD4 cell count. Failing to achieve CD4 recovery with continuous viral load suppression is rare for naïve patients initiating cART in routine clinical practice, but takes substantially longer in patients who initiate antiretroviral therapy at low CD4 cell counts.
Authors: Jeffrey A Boatman; Jason V Baker; Sean Emery; Hansjakob Furrer; David M Mushatt; Dalibor Sedláček; Jens D Lundgren; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Margaret T May; Jorg-Janne Vehreschild; Adam Trickey; Niels Obel; Peter Reiss; Fabrice Bonnet; Murielle Mary-Krause; Hasina Samji; Matthias Cavassini; Michael John Gill; Leah C Shepherd; Heidi M Crane; Antonella d'Arminio Monforte; Greer A Burkholder; Margaret M Johnson; Paz Sobrino-Vegas; Pere Domingo; Robert Zangerle; Amy C Justice; Timothy R Sterling; José M Miró; Jonathan A C Sterne; Andrew Boulle; Christoph Stephan; Jose M Miro; Matthias Cavassini; Geneviève Chêne; Dominique Costagliola; François Dabis; Antonella D'Arminio Monforte; Julia Del Amo; Ard Van Sighem; Gerd Fätkenheuer; John Gill; Jodie Guest; David Hans-Ulrich Haerry; Robert Hogg; Amy Justice; Leah Shepherd; Neils Obel; Heidi Crane; Colette Smith; Peter Reiss; Michael Saag; Tim Sterling; Ramon Teira; Matthew Williams; Robert Zangerle; Jonathan Sterne; Margaret May; Suzanne Ingle; Adam Trickey Journal: Clin Infect Dis Date: 2016-03-29 Impact factor: 9.079
Authors: Natalia Gawron; M Choiński; B Szymańska-Kotwica; A Pluta; M Sobańska; A R Egbert; A Desowska; T Wolak; A Horban; E Firląg-Burkacka; P Bieńkowski; H Sienkiewicz-Jarosz; A Scińska-Bieńkowska; B Biswal; S M Rao; R Bornstein; E Łojek Journal: J Neurovirol Date: 2018-10-08 Impact factor: 2.643